Calmark receives order from Jordan

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Jordan, Alpha Tech Est., covering the Calmark Neo platform and bilirubin tests.

As previously disclosed, an exclusive distributor agreement has been signed with Alpha Tech Est. regarding sales and marketing of Calmark Neo in Jordan. Today’s order is of less economic importance, but highly significant in perspective of the launch.  

“We are very happy for the order from Alpha Tech, which shows that the launch is now under way in Jordan. It has taken some time because of the COVID-19 situation, which has rendered sales of products unrelated to COVID-19 more difficult,” says Magdalena Tharaldsen, Director International Business Development at Calmark. “The units will be distributed  to Alpha Tech’s largest and most important customers in Jordan.”

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

 

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.